SecBot SecBot
8-K ·Filed Jun 10, 2026

SNDX

Syndax Pharmaceuticals Inc
NEUTRAL
Impact 5/10
Horizonweeks Processed5mo ago SEC0001193125-26-266027
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight • Neutral

Monitor for use of proceeds toward pipeline catalysts (revumenib, entinostat) and any subsequent equity issuances that could accelerate dilution. The convertible structure provides a low-cost financing source (2.25% coupon) but creates overhang given the conversion premium. Watch for any fundamental change events that could trigger note repurchase rights.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$17.91
T+0 close · Jun 10, 2026 · via day close
Latest settled
+14.80%
T+60 · $20.56
Vs SPY
+10.40%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 11 $17.91entry
  2. T+1 · 5mo ago +1.90%α +1.36% · $18.25
  3. T+5 · 5mo ago +6.31%α +5.88% · $19.04
  4. T+20 · 4mo ago +38.69%α +36.80% · $24.84
  5. T+60 · 2mo ago +14.80%α +10.40% · $20.56
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Syndax Pharmaceuticals issued $250 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 in a private placement, generating net proceeds of approximately $243 million. The company plans to use the funds for general corporate purposes including R&D, commercialization, and business development. The notes are convertible into common stock at an initial rate of 40.3894 shares per $1,000 principal, with a maximum potential dilution of up to 13,631,400 shares.

Key Financial Metrics

Offering Size
$250.0M

Key Facts

  • Issued $250 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031
  • Net proceeds of approximately $243 million after fees and expenses
  • Initial conversion rate of 40.3894 shares per $1,000 principal amount of Notes
  • Maximum of 13,631,400 shares of common stock may be issued upon conversion
  • Notes mature on June 15, 2031
  • Interest payable semi-annually at 2.25% per year
  • Notes are not redeemable by the company prior to June 20, 2029
  • Proceeds to be used for general corporate purposes including R&D, commercialization, and business development

Financial Impact

$250 million convertible note issuance with $243 million net proceeds; potential dilution of up to 13.6 million shares (approximately 8-10% of current shares outstanding based on $1.6B market cap)

debtdilutioncash

Risk Factors

  • Potential dilution of up to 13.6 million shares upon conversion
  • Interest expense of ~$5.6 million annually on the notes
  • Conversion may be accelerated if stock price trades above 130% of conversion price for 20 of 30 consecutive trading days
  • Fundamental change events could trigger mandatory repurchase at 100% of principal plus accrued interest

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-266027
Document: d105044dex42.htm0001193125-26-266027
Document: d105044d8k.htm0001193125-26-266027
Document: 0001193125-26-266027-index-headers.html0001193125-26-266027
Document: 0001193125-26-266027-index.html0001193125-26-266027
Document: 0001193125-26-266027.txt0001193125-26-266027

US Market Status

Market Closed · Opens in 7h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 10, 2026